# Safety and Immunogenicity of an Inactivated EV71 Vaccine in Infants

> **NCT01421121** · PHASE2 · COMPLETED · sponsor: **Sinovac Biotech Co., Ltd** · enrollment: 540 (actual)

## Conditions studied

- Infection, Viral, Enterovirus

## Interventions

- **BIOLOGICAL:** 100U EV71 vaccine with adjuvant
- **BIOLOGICAL:** 200 U EV71 vaccine with adjuvant
- **BIOLOGICAL:** 400U EV71 vaccine with adjuvant
- **BIOLOGICAL:** 200U EV71 vaccine without adjuvant
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT01421121
- **Lead sponsor:** Sinovac Biotech Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-06
- **Primary completion:** 2011-09
- **Final completion:** 2011-12
- **Target enrollment:** 540 (ACTUAL)
- **Last updated:** 2012-11-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01421121

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01421121, "Safety and Immunogenicity of an Inactivated EV71 Vaccine in Infants". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01421121. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*